Valneva (NASDAQ:VALN) Hits New 12-Month Low After Analyst Downgrade

Valneva SE Sponsored ADR (NASDAQ:VALN) reached a new 52-week low during mid-day trading on Wednesday after The Goldman Sachs Group downgraded the stock from a neutral rating to a sell rating. The Goldman Sachs Group now has a $4.90 price target on the stock. Valneva traded as low as $5.22 and last traded at $5.25, with a volume of 463879 shares changing hands. The stock had previously closed at $5.93.

Separately, Guggenheim set a $11.00 target price on shares of Valneva in a research report on Thursday, April 16th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Valneva has an average rating of “Hold” and a consensus target price of $11.98.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VALN. China Universal Asset Management Co. Ltd. acquired a new position in shares of Valneva during the fourth quarter valued at approximately $44,000. Marex Group plc purchased a new position in shares of Valneva in the second quarter valued at approximately $64,000. XTX Topco Ltd purchased a new position in shares of Valneva in the fourth quarter valued at approximately $94,000. VSM Wealth Advisory LLC lifted its position in shares of Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after acquiring an additional 5,000 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Valneva in the third quarter valued at approximately $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Stock Performance

The firm has a market cap of $452.08 million, a PE ratio of -3.32 and a beta of 1.97. The firm has a 50-day moving average price of $8.65 and a two-hundred day moving average price of $9.08. The company has a quick ratio of 1.85, a current ratio of 2.38 and a debt-to-equity ratio of 1.52.

Valneva (NASDAQ:VALN) last released its earnings results on Sunday, February 15th. The company reported ($0.68) earnings per share for the quarter. The firm had revenue of $55.92 million during the quarter. Valneva had a negative net margin of 67.64% and a negative return on equity of 76.81%. Research analysts forecast that Valneva SE Sponsored ADR will post -0.81 EPS for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.